Clinical Programs
Stay current with evidence-based medicine. Get curated briefings on new clinical trial results, updated treatment guidelines, and integrative approaches—all rated by evidence quality.
Start This BriefingWho This Is For
What Your Briefings Cover
Clinical Trial Results
New findings from major trials, with analysis of methodology, effect sizes, and clinical significance.
Treatment Guidelines
Updated protocols from major medical societies, with comparison to previous recommendations.
Drug Interactions
New contraindications, interactions, and safety updates. What you need to know for patient safety.
Integrative Approaches
Evidence-based complementary therapies, with ratings on research quality and clinical applicability.
Sample Briefing Excerpt
"GLP-1 Agonists for NASH: ESSENCE Trial Results"
Evidence Rating: A (High-quality RCT)
The ESSENCE trial (n=1,094) demonstrated that semaglutide 2.4mg weekly achieved NASH resolution without worsening fibrosis in 59% of patients vs. 17% placebo (p<0.001).
Clinical implications:
- First pharmacotherapy to show significant NASH resolution in Phase 3
- Effect size comparable to bariatric surgery in matched populations
- Weight loss of 12.3% may account for majority of hepatic benefit
Practice considerations: FDA approval expected Q2 2025. Current off-label use for NASH is increasing; ensure liver function monitoring and consider gastric side effect profile in patients with portal hypertension.
Stay Current with Evidence
Get the clinical updates that matter, curated and rated by evidence quality.
Start Your Briefing